Moderna and Merck said positive Phase 3 data support intismeran autogene, an individualized neoantigen (INT) mRNA vaccine, in combination with Keytruda (pembrolizumab). In the randomized INTerpath-001 trial (NCT05933577), Merck/Moderna reported improved recurrence-free survival and distant metastasis-free survival versus Keytruda alone, based on 1,137 participants. The companies positioned the result as a meaningful efficacy signal for a personalized approach in surgically resected melanoma, where durability of response has been a key differentiator. Investors also tracked downstream implications for enabling technologies used to identify neoantigen targets from tumor sequencing. Separate trading read-through extended into sequencing suppliers including Illumina and PacBio, reflecting the therapy’s dependency on patient-specific genomic inputs. The updates add momentum to a segment where earlier skepticism has surrounded mRNA cancer-vaccine deliverability and clinical reliability.